WO2026130526 - TRICYCLIC COMPOUND AND MEDICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/130526
Publication Date
25.06.2026
International Application No.
PCT/CN2025/143917
International Filing Date
19.12.2025
Title **
[English]
TRICYCLIC COMPOUND AND MEDICAL USE THEREOF
[French]
COMPOSÉ TRICYCLIQUE ET UTILISATION MÉDICALE DE CELUI-CI
[Chinese]
三元稠环类化合物及其医药用途
Applicants **
HANGZHOU BAICREAT PHARMA-TECH CO., LTD.
Inventors
ZHANG, Fengmin
ZHANG, Sicheng
SHAN, Lihong
Priority Data
202411889705.3
20.12.2024
CN
202511027326.8
24.07.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2268 | |
| EPO | Filing, Examination, Granting | 18281 | |
| Japan | Filing, Examination, Granting | 2594 | |
| South Korea | Filing, Examination, Granting | 3071 | |
| USA | Filing, Examination, Granting | 6140 |
Total:
32,354
Contact Us
Abstract[English]
The present invention relates to the technical field of medicine, and specifically relates to a Cbl-b small molecule inhibitor, a preparation method therefor, and the medical use thereof. Provided in the present invention are a Cbl-b small molecule inhibitor represented by formula (I), a composition thereof and the use thereof. The compound can be used for treating or preventing Cbl-b mediated diseases or disorders and related diseases or disorders.[French]
La présente invention concerne le domaine technique de la médecine, et concerne plus particulièrement un inhibiteur de petite molécule Cbl-b, un procédé de préparation de celui-ci, et l'utilisation médicale de celui-ci. La présente invention concerne un inhibiteur de petite molécule Cbl-b représenté par la formule (I), une composition de celui-ci et l'utilisation de celui-ci. Le composé peut être utilisé pour traiter ou prévenir des maladies ou troubles médiés par Cbl-b et des maladies ou troubles associés.[Chinese]
本发明涉及医药技术领域，具体涉及Cbl-b小分子抑制剂、其制备方法及其在医药上的应用。本发明提供了一种式(I)所示的Cbl-b小分子抑制剂及其组合物和用途，所述化合物可以用于治疗或预防Cbl-b介导的疾病或病症及相关疾病或病症。